Gilead Acquires CymaBay, Enhances Liver Disease Portfolio
Key Highlights Gilead Sciences, Inc. (GILD) acquires CymaBay Therapeutics, Inc. (CBAY) for approx. $4.3 billion, bolstering its liver disease…
Browsing Tag
Daniel O’Day
2 posts
Gilead Acquires CymaBay in $4.3 Billion Deal
Key Highlights Gilead Sciences announces acquisition of CymaBay Therapeutics for $4.3 billion, bolstering its liver disease treatment offerings. Seladelpar, CymaBay’s lead product…